Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStopping semaglutide is a decision best made with your prescriber, not alone. Clinical trial data show that when people stop semaglutide, a significant portion of the weight lost during treatment tends to return within 12 months, which is why the timing, method and follow-up plan all matter. These are prescription-only medicines, and any plan to stop semaglutide should involve the clinician who oversees your care.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 extension study followed participants who had completed 68 weeks on semaglutide 2.4 mg and then stopped treatment, without continuing any structured support. Within 12 months of stopping, most of the body-weight reduction achieved during the trial had reversed. Hunger returned, appetite regulation shifted back, and energy intake rose. This is not a personal failing. Semaglutide works by activating GLP-1 receptors involved in appetite signalling and gastric emptying; when the medicine is no longer present, those pathways return to their prior state. The STEP 1 trial, published in the New England Journal of Medicine, is the primary evidence base for understanding what semaglutide does — and what happens when it stops doing it. If you are considering stopping, knowing this in advance lets you plan, rather than be caught off guard. Read more about the broader evidence base on our semaglutide overview page.
None of this means you must stay on treatment indefinitely. It means the transition deserves thought.
Unlike some medicines (antidepressants, for example) semaglutide does not carry a pharmacological dependence that requires a mandatory taper. Stopping abruptly is not dangerous in the way that stopping certain other medications would be. That said, many prescribers do recommend a step-down approach for practical reasons. Coming off a higher dose gradually may make the return of appetite feel less sudden, and it gives you time to consolidate the dietary habits built during treatment. For anyone on 1.7 mg or 2.4 mg, stepping back to a lower dose for a few weeks before stopping entirely is worth discussing with your prescriber. The NHS semaglutide medicine page is a useful reference for understanding the medicine's general profile. If you want to understand how semaglutide is started and titrated in the first place, our guide to starting semaglutide explains the schedule in plain terms. Never adjust your dose or timing without speaking to your prescriber first; what feels like a sensible self-managed taper may not fit your clinical picture.
There are several reasonable reasons to stop semaglutide. You may have reached your weight-management goal and feel confident maintaining it with lifestyle measures alone. You may be planning a pregnancy, since semaglutide is not recommended during pregnancy, breastfeeding, or when trying to conceive, and a wash-out period before conception is advised. You might be experiencing persistent side effects that outweigh the benefits at your current dose. Or the cost of ongoing private treatment may no longer be manageable. All of these are legitimate clinical conversations, and patients accessing Wegovy in Edinburgh can raise them directly with a local GPhC-registered prescriber. Our page on when to consider stopping Wegovy goes into the specific circumstances in more detail. On the other side, some people stop semaglutide because they feel well and assume the effect is permanent. The trial data above suggest caution there. A prescriber can help you distinguish between a good stopping point and a premature one. That distinction is exactly what a clinical review is for. You can also explore other weight-management approaches to understand what support sits alongside or after treatment.
If you and your prescriber agree that stopping semaglutide is the right move, a few practical steps make the transition smoother. First, agree whether you are stepping down gradually or stopping at your current dose. Second, think about what replaces the appetite-reduction effect: higher-protein meals, regular structured eating times and continued physical activity are the most evidence-supported strategies for preserving weight lost during treatment. Third, make sure you have a clear plan for follow-up. Weight management does not end with the last injection. Our dedicated page on stopping Wegovy covers the Wegovy-specific details including what to do with any remaining pens. Unused injectable medicines should be disposed of safely; a sharps container is the right route for pens rather than household waste. If circumstances change and you want to consider restarting, treatment can be reassessed. You can begin that conversation at any time through our free consultation, where a GPhC-registered prescriber reviews your case the same day. Your notes from previous treatment, including any dose history you can share, will support that review. One thing worth knowing: if you have been on a recognised clinical programme and are considering switching provider rather than stopping entirely, our Wegovy supply page explains how transfer patients are assessed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.